The first issue is that Medicare Part D’s implementation was under condition that Medicare cannot negotiate drug prices. This means that Medicare and drug manufacturers cannot negotiate discounts or any form of price reduction the way other insurances, such as Medicaid, can (Dalen, 2009). Without this allowance of negotiation, coupons and discounts are out of the question for those covered via Medicare—the insurance company has to pay the full price of every drug, and that’s the only choice for Medicare. To balance the expenses of having to pay for medications at full price, Medicare then has to turn to other forms of making money and reducing their costs, creating the second key issue of Medicare: the doughnut hole. This second issue is a hugely consequential one for beneficiaries, therefore the doughnut hole and the effects it has on the medication use of Medicare beneficiaries with Part D coverage will be the main focus of this
The first issue is that Medicare Part D’s implementation was under condition that Medicare cannot negotiate drug prices. This means that Medicare and drug manufacturers cannot negotiate discounts or any form of price reduction the way other insurances, such as Medicaid, can (Dalen, 2009). Without this allowance of negotiation, coupons and discounts are out of the question for those covered via Medicare—the insurance company has to pay the full price of every drug, and that’s the only choice for Medicare. To balance the expenses of having to pay for medications at full price, Medicare then has to turn to other forms of making money and reducing their costs, creating the second key issue of Medicare: the doughnut hole. This second issue is a hugely consequential one for beneficiaries, therefore the doughnut hole and the effects it has on the medication use of Medicare beneficiaries with Part D coverage will be the main focus of this